AXL and neoplasm: The median survival was 755 days in those GBM patients exhibiting P-AXL expression in hypercellular tumor areas (pattern ii) versus 485 days in those with P-AXL expression in the tumor vasculature and hypercellular tumor areas (pattern iii, Figure 5).